At a glance
- Moderna and Merck’s mRNA melanoma vaccine, intismeran autogene, succeeded in a late-stage trial announced August 19–20, 2026.
- The underlying mRNA science traces to Katalin Karikó, a Hungarian immigrant and 2023 Nobel laureate.
- Moderna was co-founded by Noubar Afeyan, who came to the U.S. as an international student.
- A new $100,000 H-1B payment requirement and a finalized DHS rule ending “duration of status” for students and exchange visitors are both now facing active legal challenges.
This Week’s Breakthrough
This week, Moderna and Merck announced that their personalized mRNA vaccine, intismeran autogene, succeeded in a late-stage clinical trial, reducing melanoma recurrence when paired with the immunotherapy drug Keytruda. Researchers are calling it the first positive late-stage trial for any mRNA-based cancer therapy, and doctors are already studying whether the same approach could work against other tumors. It is genuinely exciting medical news. It is also, once again, a story about immigration.
The Scientist Behind the Discovery
The science behind this week’s headlines did not begin in a corporate lab. It began with Katalin Karikó, a biochemist who left Hungary in 1985 with her husband and two-year-old daughter, having sewn the family’s savings into a teddy bear because they were not permitted to take money out of the country any other way. For nearly two decades afterward, Karikó’s research into messenger RNA was dismissed by funders and, at one low point, cost her a tenure-track position at the University of Pennsylvania. She kept working. In 2023, she and her research partner Drew Weissman won the Nobel Prize in Physiology or Medicine for discoveries that made the COVID-19 mRNA vaccines, and now this week’s melanoma vaccine, possible.
The Company an Immigrant Built
An immigrant entrepreneur also played a central role in Moderna’s creation. Noubar Afeyan, the company’s co-founder and chairman, fled to Canada as a teenager when Lebanon’s civil war broke out, then came to the United States as an international student to earn his Ph.D. at MIT. He went on to found the venture firm Flagship Pioneering, which incubated Moderna, and became a U.S. citizen in 2008. Together, Karikó’s scientific contributions and Afeyan’s entrepreneurial work offer a powerful example of how immigrants have helped strengthen America’s biotechnology and scientific leadership.
A Century-Long Pattern
That pattern is not new. Albert Einstein arrived at Princeton in 1933 as a refugee from Nazi Germany. His theoretical work on mass and energy became the scientific foundation of the nuclear age, and he was among the scientists who later pressed the U.S. government to take atomic research seriously. A generation after that, immigrants and the children of immigrants helped build what we now call Silicon Valley, from Sergey Brin at Google to Andy Grove at Intel to Jerry Yang at Yahoo. For a century, the United States has been the place where the world’s most driven scientists and engineers come to do their best work. That has never been an accident of geography. It is a function of immigration policy.
The Pathways Now Under Pressure
Which brings us to the present. Karikó came to the United States on a visa to take a research position. Afeyan came on a student visa and built his career through years of employment-based sponsorship. Today, those same broad categories carry the next generation of researchers into American labs, hospitals, and pharmaceutical companies: F-1 student status leading into Optional Practical Training, the H-1B specialty occupation visa, and the O-1A visa for individuals of extraordinary ability in the sciences. For multinational biotech and pharmaceutical companies moving scientists and managers between global offices, the L-1A and L-1B intracompany transfer visas do similar work. On the permanent side, researchers who want to stay long-term typically pursue an employment-based green card, whether through the standard PERM labor certification process or, for those who qualify, the EB-1A extraordinary ability category or the EB-2 National Interest Waiver, both of which allow certain scientists to self-petition without a permanent job offer. They are also facing real headwinds. A $100,000 payment requirement now applies to certain new H-1B petitions involving beneficiaries outside the United States, subject to specified exceptions. Separately, DHS finalized a rule replacing “duration of status” admission for F, J, and I nonimmigrants with fixed periods of admission, scheduled to take effect September 15, 2026. A coalition of universities and higher-education associations sued to block the rule on August 18, 2026, so its effective date is currently being litigated. These developments can add cost and uncertainty at exactly the moment biotech, AI, and advanced manufacturing are competing globally for talent.
Why This Matters
None of this is a partisan point. It is a practical one. The scientists whose decades of work led to this week’s cancer vaccine news came to America because the door was open enough, for long enough, for that work to happen. Keeping employment- and research-based immigration pathways functional is not a side issue for the life sciences industry. It is the pipeline.
If you or your organization have questions about how these visa categories work, or how recent policy changes may affect your ability to recruit or retain international researchers, physicians, or engineers, please do not hesitate to contact the immigration and nationality lawyers at NPZ Law Group. You can reach us by emailing info@visaserve.com or by visiting our website at www.visaserve.com for more information.
Frequently Asked Questions
How did Katalin Karikó, the scientist behind the mRNA breakthrough, come to the United States?
Karikó left Hungary in 1985 to take a postdoctoral research position in the United States, a path that today typically runs through a combination of exchange visitor, student, or employment-based visa categories before leading to permanent residence.
What visa categories do U.S. research institutions typically use to hire foreign-born scientists?
The most common pathways are the H-1B specialty occupation visa, the O-1A extraordinary ability visa, and the L-1A/L-1B intracompany transfer visas for multinational employers, followed on the permanent side by employment-based green card categories such as PERM labor certification, the EB-1A for outstanding researchers, and the EB-2 National Interest Waiver.
Does the new $100,000 H-1B fee apply to every employer?
The fee applies to many new H-1B petitions filed for workers who are currently outside the United States. It does not apply to current H-1B holders or, in most cases, to workers already in the U.S. changing status. The fee is the subject of active litigation, so employers should confirm current requirements before filing.
How could the new international student status rule affect research pipelines?
DHS finalized a rule replacing open-ended “duration of status” admission for F-1 students, J-1 exchange visitors, and I nonimmigrants with fixed admission periods, scheduled to take effect September 15, 2026. A coalition of universities and higher-education groups sued DHS on August 18, 2026 to block the rule, so its effective date is currently in question. If it takes effect, the change is expected to add administrative steps and planning considerations for students, universities, and employers as they navigate degree programs, OPT, exchange programs, and later employment-based sponsorship.
Why does immigration policy matter to the life sciences industry specifically?
Much of the foundational research behind recent breakthroughs in mRNA therapeutics, oncology, and biotechnology more broadly has come from foreign-born scientists who entered the United States through student and employment-based visa categories, so changes to those categories directly affect the talent pipeline for future discoveries.
Sources: Reuters, NBC News, STAT News, and The Washington Post reporting on the Moderna/Merck melanoma vaccine trial results (August 19–20, 2026); National Academies of Sciences, Forbes, and Carnegie Corporation profiles of Katalin Karikó; Flagship Pioneering biographical information on Noubar Afeyan; USCIS and White House guidance on the H-1B payment requirement; and DHS/Federal Register materials on the Duration of Status final rule and related litigation.